{'fraction_non_alphanumeric': 0.03496503496503497, 'fraction_numerical': 0.027972027972027972, 'mean_word_length': 5.067796610169491, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Clinical phase II study of TK-117 by Cooperative Study Group. Effects on gastric cancer].

A clinical phase II study of TK-117, one of the derivatives of FUDR, was performed in 18 patients with gastric cancer by our Cooperative Study Group of Cancer Chemotherapy. Fourteen cases were evaluable and 3 of these showed partial response, giving a response rate of 21.4%. Toxic manifestations were experienced in fifteen of 18 cases (83.3%). Gastrointestinal toxicity was major and severe, especially diarrhea, which impeded the continuation of administration. This study revealed the usefulness of TK-117 for gastric cancer, but also the necessity of overcoming its toxicity, especially gastrointestinal complications.